{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T14:57:30Z","timestamp":1725721050982},"publisher-location":"New York, NY","reference-count":122,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781461458562"},{"type":"electronic","value":"9781461458579"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-1-4614-5857-9_20","type":"book-chapter","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T22:26:43Z","timestamp":1364509603000},"page":"381-403","source":"Crossref","is-referenced-by-count":3,"title":["Role of Genetic Polymorphisms in the Angiogenesis Pathway and Non-small-Cell Lung Cancer Tumor Behavior: Implications in Risk Assessment and Clinical Outcome"],"prefix":"10.1007","author":[{"given":"Ramon Andrade","family":"de Mello","sequence":"first","affiliation":[]},{"given":"Michael","family":"Luis","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[]},{"given":"Venceslau","family":"Hespanhol","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,3,1]]},"reference":[{"key":"20_CR00201","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.2005.10.462","volume":"23","author":"A Alberg","year":"2005","unstructured":"Alberg A, Brock M, Samet J (2005) Epidemiology of lung cancer: looking to the future. J\u00a0Clin Oncol 23:3175\u20133185","journal-title":"J Clin Oncol"},{"key":"20_CR00202","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/tc.3.3.242","volume":"3","author":"A Lopez","year":"1994","unstructured":"Lopez A, Collishaw N, Piha T (1994) A descriptive model of the cigarette epidemic in developed countries. Tob Control 3:242\u2013247","journal-title":"Tob Control"},{"key":"20_CR00203","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2007.12.8322","volume":"26","author":"TR Asmis","year":"2008","unstructured":"Asmis TR, Ding K, Seymour L et\u00a0al (2008) Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26:54\u201359","journal-title":"J Clin Oncol"},{"key":"20_CR00204","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1378\/chest.122.3.1037","volume":"122","author":"M Brundage","year":"2002","unstructured":"Brundage M, Davies D, Mackillop W (2002) Prognostic factors in non-small cell lung cancer. Chest 122:1037\u20131057","journal-title":"Chest"},{"key":"20_CR00205","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5306\/wjco.v2.i11.367","volume":"2","author":"RA Mello de","year":"2011","unstructured":"de Mello RA, Marques DS, Medeiros R, Ara\u00fajo AM (2011) Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol 2:367\u2013376","journal-title":"World J Clin Oncol"},{"key":"20_CR00206","first-page":"2191","volume":"38","author":"Y Futamura","year":"2011","unstructured":"Futamura Y, Sawa T, Hasegawa T et\u00a0al (2011) Stereotactic radiotherapy following chemo-\u00adradiotherapy for lymph node metastasis of stage III non-small-cell lung cancer. Gan To Kagaku Ryoho 38:2191\u20132193","journal-title":"Gan To Kagaku Ryoho"},{"key":"20_CR00207","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/JTO.0b013e318186fafb","volume":"3","author":"T Hanagiri","year":"2008","unstructured":"Hanagiri T, Sugio K, Mizukami M et\u00a0al (2008) Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer. J Thorac Oncol 3:1127\u20131132","journal-title":"J Thorac Oncol"},{"key":"20_CR00208","doi-asserted-by":"crossref","first-page":"e5652","DOI":"10.1371\/journal.pone.0005652","volume":"4","author":"M Rotunno","year":"2009","unstructured":"Rotunno M, Yu K, Lubin JH et\u00a0al (2009) Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One 4:e5652","journal-title":"PLoS One"},{"key":"20_CR00209","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/0008-5472.CAN-08-2590","volume":"69","author":"N Almog","year":"2009","unstructured":"Almog N, Ma L, Raychowdhury R et\u00a0al (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69:836","journal-title":"Cancer Res"},{"key":"20_CR002010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bjc.6600625","volume":"87","author":"S Balasubramanian","year":"2002","unstructured":"Balasubramanian S, Brown N, Reed M (2002) Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 87:1057\u20131065","journal-title":"Br J Cancer"},{"key":"20_CR002011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.lungcan.2009.02.013","volume":"66","author":"B Bonnesen","year":"2009","unstructured":"Bonnesen B, Pappot H, Holmstav J, Skov BG (2009) Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 66:314\u2013318","journal-title":"Lung Cancer"},{"key":"20_CR002012","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1634\/theoncologist.12-2-201","volume":"12","author":"A Araujo","year":"2007","unstructured":"Araujo A, Ribeiro R, Azevedo I et\u00a0al (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer\u2014a review of the literature. Oncologist 12:201\u2013210","journal-title":"Oncologist"},{"key":"20_CR002013","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2007.14.8924","volume":"26","author":"C Zhu","year":"2008","unstructured":"Zhu C, Ding K, da Cunha Santos G et\u00a0al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 26:4268\u20134275","journal-title":"J Clin Oncol"},{"key":"20_CR002014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdh011","volume":"15","author":"G Selvaggi","year":"2004","unstructured":"Selvaggi G, Novello S, Torri V et\u00a0al (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15:28\u201332","journal-title":"Ann Oncol"},{"key":"20_CR002015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y et\u00a0al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128","journal-title":"Lancet Oncol"},{"key":"20_CR002016","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K et\u00a0al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388","journal-title":"N Engl J Med"},{"key":"20_CR002017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"F Shepherd","year":"2005","unstructured":"Shepherd F, Rodrigues Pereira J, Ciuleanu T et\u00a0al (2005) Erlotinib in previously treated non-\u00adsmall-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"20_CR002018","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu Y, Chen G et\u00a0al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735\u2013742","journal-title":"Lancet Oncol"},{"key":"20_CR002019","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"T Mok","year":"2009","unstructured":"Mok T, Wu Y, Thongprasert S et\u00a0al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947\u2013957","journal-title":"N Engl J Med"},{"key":"20_CR002020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nrc1506","volume":"4","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Fukuoka M, Baselga J (2004) Gefitinib\u2014a novel targeted approach to treating cancer. Nat Rev Cancer 4:979\u2013987","journal-title":"Nat Rev Cancer"},{"key":"20_CR002021","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/157489212798357994","volume":"7","author":"RA Mello de","year":"2012","unstructured":"de Mello RA, Costa BM, Reis RM, Hespanhol V (2012) Insights into angiogenesis in non-\u00adsmall cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent Pat Anticancer Drug Discov 7:118\u2013131","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"20_CR002022","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","volume":"26","author":"B Schneider","year":"2008","unstructured":"Schneider B, Wang M, Radovich M et\u00a0al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672\u20134678","journal-title":"J Clin Oncol"},{"key":"20_CR002023","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1101\/SQB.1955.020.01.025","volume":"20","author":"PM Sheppard","year":"1955","unstructured":"Sheppard PM (1955) Genetic variability and polymorphism: synthesis. Cold Spring Harb Symp Quant Biol 20:271\u2013275","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"20_CR002024","first-page":"437","volume":"21","author":"TC Hsu","year":"1958","unstructured":"Hsu TC, Klatt O (1958) Mammalian chromosomes in\u00a0vitro. IX. On genetic polymorphism in cell populations. J Natl Cancer Inst 21:437\u2013473","journal-title":"J Natl Cancer Inst"},{"key":"20_CR002025","volume-title":"Cancer: principles and practice of oncology","author":"A El-Khoueiry","year":"2011","unstructured":"El-Khoueiry A, Lenz H (2011) Pharmacogenomics. In: DeVita VT, Lawrence TS, Rosenberg SA (eds) Cancer: principles and practice of oncology, 9th edn. Lippincott Williams & Wilkins, Philadelphia","edition":"9"},{"key":"20_CR002026","unstructured":"Marques Santos DS (2012) Papel progn\u00f3stico e preditivo do polimorfismo da IL-8-251 T\/A no carcinoma epitelial do ov\u00e1rio. Master degree, Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, University of Porto"},{"key":"20_CR002027","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/35057149","volume":"409","author":"R Sachidanandam","year":"2001","unstructured":"Sachidanandam R, Weissman D, Schmidt SC et\u00a0al (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928\u2013933","journal-title":"Nature"},{"key":"20_CR002028","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL (2002) Hypoxia\u2014a key regulatory factor in tumour growth. Nat Rev Cancer 2:38\u201347","journal-title":"Nat Rev Cancer"},{"key":"20_CR002029","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2174\/156652409788167087","volume":"9","author":"S Rockwell","year":"2009","unstructured":"Rockwell S, Dobrucki IT, Kim EY et\u00a0al (2009) Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 9:442\u2013458","journal-title":"Curr Mol Med"},{"key":"20_CR002030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1098\/rspb.1933.0044","volume":"113","author":"H Crabtree","year":"1933","unstructured":"Crabtree H, Cramer W (1933) The action of radium on cancer cells. II.\u2013some factors determining the susceptibility of cancer cells to radium. Proc R Soc Ser B 113:238\u2013250","journal-title":"Proc R Soc Ser B"},{"key":"20_CR002031","first-page":"1","volume":"24","author":"G Schwarz","year":"1909","unstructured":"Schwarz G (1909) \u00dcber Desensibilisierung gegen R\u00f6ntgen- und Radiumstrahlen. Munch Med Wochenschr 24:1\u20132","journal-title":"Munch Med Wochenschr"},{"key":"20_CR002032","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10555-007-9063-1","volume":"26","author":"DA Chan","year":"2007","unstructured":"Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26:333\u2013339","journal-title":"Cancer Metastasis Rev"},{"key":"20_CR002033","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10555-007-9060-4","volume":"26","author":"J Kim","year":"2007","unstructured":"Kim J, Gao P, Dang CV (2007) Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 26:291\u2013298","journal-title":"Cancer Metastasis Rev"},{"key":"20_CR002034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijrobp.2005.04.049","volume":"63","author":"J Varlotto","year":"2005","unstructured":"Varlotto J, Stevenson MA (2005) Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63:25\u201336","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"20_CR002035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000088285","volume":"69","author":"M Boogaerts","year":"2005","unstructured":"Boogaerts M, Mittelman M, Vaupel P (2005) Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models. Oncology 69:22\u201330","journal-title":"Oncology"},{"key":"20_CR002036","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","volume":"26","author":"L Gray","year":"1953","unstructured":"Gray L, Conger A, Ebert M et\u00a0al (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638\u2013648","journal-title":"Br J Radiol"},{"key":"20_CR002037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00066-005-1277-y","volume":"181","author":"R Mayer","year":"2005","unstructured":"Mayer R, Hamilton-Farrell MR, van der Kleij AJ et\u00a0al (2005) Hyperbaric oxygen and radiotherapy. Strahlenther Onkol 181:113\u2013123","journal-title":"Strahlenther Onkol"},{"key":"20_CR002038","first-page":"1","volume":"30","author":"J Feldmeier","year":"2003","unstructured":"Feldmeier J, Carl U, Hartmann K, Sminia P (2003) Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea Hyperb Med 30:1\u201318","journal-title":"Undersea Hyperb Med"},{"key":"20_CR002039","doi-asserted-by":"crossref","unstructured":"Bennett M, Feldmeier J, Smee R, Milross C (2005) Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev (4):CD005007","DOI":"10.1002\/14651858.CD005007.pub2"},{"key":"20_CR002040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1053-4296(96)80032-4","volume":"6","author":"J Overgaard","year":"1996","unstructured":"Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6:10\u201321","journal-title":"Semin Radiat Oncol"},{"key":"20_CR002041","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","volume":"25","author":"J Overgaard","year":"2007","unstructured":"Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25:4066\u20134074","journal-title":"J Clin Oncol"},{"key":"20_CR002042","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(02)00929-4","volume":"3","author":"JHAM Kaanders","year":"2002","unstructured":"Kaanders JHAM, Bussink J, van der Kogel AJ (2002) ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3:728\u2013737","journal-title":"Lancet Oncol"},{"key":"20_CR002043","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fphar.2012.00094","volume":"3","author":"BF Jordan","year":"2012","unstructured":"Jordan BF, Sonveaux P (2012) Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Front Pharmacol 3:94","journal-title":"Front Pharmacol"},{"key":"20_CR002044","first-page":"123","volume":"12","author":"AN Rewari","year":"2006","unstructured":"Rewari AN, Haffty BG, Wilson LD et\u00a0al (2006) Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials. Cancer J 12:123\u2013129","journal-title":"Cancer J"},{"key":"20_CR002045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/1097-0215(20000820)90:4<206::AID-IJC4>3.0.CO;2-O","volume":"90","author":"KB Roberts","year":"2000","unstructured":"Roberts KB, Urdaneta N, Vera R et\u00a0al (2000) Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous\u2010cell carcinoma of the cervix. Int J Cancer 90:206\u2013223","journal-title":"Int J Cancer"},{"key":"20_CR002046","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/1471-2407-11-504","volume":"11","author":"KL Bennewith","year":"2011","unstructured":"Bennewith KL, Dedhar S (2011) Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 11:504","journal-title":"BMC Cancer"},{"key":"20_CR002047","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/1078-0432.CCR-07-4020","volume":"14","author":"MR Albertella","year":"2008","unstructured":"Albertella MR, Loadman PM, Jones PH et\u00a0al (2008) Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14:1096\u20131104","journal-title":"Clin Cancer Res"},{"key":"20_CR002048","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-009-1188-1","volume":"65","author":"MB Jameson","year":"2010","unstructured":"Jameson MB, Rischin D, Pegram M et\u00a0al (2010) A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65:791\u2013801","journal-title":"Cancer Chemother Pharmacol"},{"key":"20_CR002049","doi-asserted-by":"crossref","first-page":"e5052","DOI":"10.1371\/journal.pone.0005052","volume":"4","author":"CH Chen","year":"2009","unstructured":"Chen CH, Lai JM, Chou TY et\u00a0al (2009) VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K\/AKT pathway. PLoS One 4:e5052","journal-title":"PLoS One"},{"key":"20_CR002050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3816\/CLC.2007.s.002","volume":"8","author":"N Choong","year":"2008","unstructured":"Choong N, Salgia R, Vokes E (2008) Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer 8:52\u201360","journal-title":"Clin Lung Cancer"},{"key":"20_CR002051","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"R Kerbel","year":"2008","unstructured":"Kerbel R (2008) Tumor angiogenesis. N Engl J Med 358:2039\u20132049","journal-title":"N Engl J Med"},{"key":"20_CR002052","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1590\/S0102-86502000000300006","volume":"15","author":"RP Gonz\u00e1lez","year":"2000","unstructured":"Gonz\u00e1lez RP, Leyva A, Melo RAB et\u00a0al (2000) M\u00e9todo para estudo in\u00a0vivo da angiog\u00eanese: indu\u00e7\u00e3o de neovasculariza\u00e7\u00e3o na c\u00f3rnea de coelho. Acta Cir Bras 15:168\u2013173","journal-title":"Acta Cir Bras"},{"key":"20_CR002053","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12032-011-9924-x","volume":"29","author":"SJ An","year":"2012","unstructured":"An SJ, Huang YS, Chen ZH et\u00a0al (2012) Posttreatment plasma VEGF levels may be \u00adassociated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol 29:627\u2013632","journal-title":"Med Oncol"},{"key":"20_CR002054","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2005.09.005","volume":"51","author":"R Bremnes","year":"2006","unstructured":"Bremnes R, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143\u2013158","journal-title":"Lung Cancer"},{"key":"20_CR002055","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"H Dvorak","year":"2002","unstructured":"Dvorak H (2002) Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368\u20134380","journal-title":"J Clin Oncol"},{"key":"20_CR002056","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-11-0379","volume":"17","author":"DM Glubb","year":"2011","unstructured":"Glubb DM, Cerri E, Giese A et\u00a0al (2011) Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 17:5257\u20135267","journal-title":"Clin Cancer Res"},{"key":"20_CR002057","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/1078-0432.CCR-07-1154","volume":"14","author":"A Dowlati","year":"2008","unstructured":"Dowlati A, Gray R, Sandler A et\u00a0al (2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab\u2014an Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:1407\u20131412","journal-title":"Clin Cancer Res"},{"key":"20_CR002058","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1200\/JCO.2007.11.3985","volume":"25","author":"D Duda","year":"2007","unstructured":"Duda D, Jain R, Willett C (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033\u20134042","journal-title":"J Clin Oncol"},{"key":"20_CR002059","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-33177-3_1","volume-title":"Tumor angiogenesis: basic concepts and cancer therapy","author":"J Folkman","year":"2008","unstructured":"Folkman J (2008) Tumor angiogenesis: from bench to bedside. In: Marm\u00e9 D, Fusenig N (eds) Tumor angiogenesis: basic concepts and cancer therapy, 8th edn. Springer, Berlin, pp 3\u201328","edition":"8"},{"key":"20_CR002060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/339058a0","volume":"339","author":"J Folkman","year":"1989","unstructured":"Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58\u201361","journal-title":"Nature"},{"key":"20_CR002061","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/1471-2407-10-431","volume":"10","author":"X Guan","year":"2010","unstructured":"Guan X, Yin M, Wei Q et\u00a0al (2010) Genotypes and haplotypes of the VEGF gene and survival in\u00a0loc.lly advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10:431","journal-title":"BMC Cancer"},{"key":"20_CR002062","first-page":"142","volume":"24","author":"Q Dong","year":"2002","unstructured":"Dong Q, Feng J, Huang J et\u00a0al (2002) [Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 24:142\u2013146","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"20_CR002063","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF03032598","volume":"7","author":"E Forgacs","year":"2001","unstructured":"Forgacs E, Z\u00f6chbauer-M\u00fcller S, Ol\u00e1h E, Minna J (2001) Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 7:6\u201313","journal-title":"Pathol Oncol Res"},{"key":"20_CR002064","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.lungcan.2009.06.010","volume":"68","author":"C Gessner","year":"2009","unstructured":"Gessner C, Rechner B, Hammerschmidt S et\u00a0al (2009) Angiogenic markers in breath condensate identify non-small cell lung cancer. Lung Cancer 68:177\u2013184","journal-title":"Lung Cancer"},{"issue":"5","key":"20_CR002065","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1007\/s11033-011-1326-9","volume":"39","author":"TT Hong","year":"2011","unstructured":"Hong TT, Zhang RX, Wu XH, Hua D (2011) Polymorphism of vascular endothelial growth factor \u22121154 G>A (rs1570360) with cancer risk: a meta-analysis of 16 case\u2013control studies. Mol Biol Rep 2012; 39(5):5283\u20135289","journal-title":"Mol Biol Rep"},{"key":"20_CR002066","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(02)07600-6","volume":"359","author":"M Shahbazi","year":"2002","unstructured":"Shahbazi M, Pravica V, Nasreen N et\u00a0al (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359:397\u2013401","journal-title":"Lancet"},{"key":"20_CR002067","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3748\/wjg.v17.i4.488","volume":"17","author":"A Ara\u00fajo","year":"2011","unstructured":"Ara\u00fajo A, Costa B, Pinto-Correia A et\u00a0al (2011) Association between EGF +61A\/G polymorphism and gastric cancer in caucasians. World J Gastroenterol 17:488\u2013492","journal-title":"World J Gastroenterol"},{"key":"20_CR002068","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canep.2010.02.004","volume":"34","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Cao C, Liang K (2010) Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. Cancer Epidemiol 34:150\u2013156","journal-title":"Cancer Epidemiol"},{"key":"20_CR002069","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1158\/1078-0432.CCR-06-2606","volume":"13","author":"B Costa","year":"2007","unstructured":"Costa B, Ferreira P, Costa S et\u00a0al (2007) Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 13:2621\u20132626","journal-title":"Clin Cancer Res"},{"key":"20_CR002070","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/0008-5472.CAN-03-3137","volume":"64","author":"D Bhowmick","year":"2004","unstructured":"Bhowmick D, Zhuang Z, Wait S, Weil R (2004) A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 64:1220\u20131223","journal-title":"Cancer Res"},{"key":"20_CR002071","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00268-008-9784-5","volume":"33","author":"G Wu","year":"2009","unstructured":"Wu G, Hasenberg T, Magdeburg R et\u00a0al (2009) Association between EGF, TGF-beta1. VEGF gene polymorphism and colorectal cancer. World J Surg 33:124\u2013129","journal-title":"World J Surg"},{"key":"20_CR002072","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1440-1843.2007.01152.x","volume":"12","author":"H Kang","year":"2007","unstructured":"Kang H, Choi J, Lee W et\u00a0al (2007) +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology 12:902\u2013905","journal-title":"Respirology"},{"key":"20_CR002073","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neulet.2004.10.055","volume":"374","author":"Y Lim","year":"2005","unstructured":"Lim Y, Kim J, Song J et\u00a0al (2005) Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett 374:157\u2013160","journal-title":"Neurosci Lett"},{"key":"20_CR002074","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s13277-012-0382-7","volume":"33","author":"RA Mello de","year":"2012","unstructured":"de Mello RA, Ferreira M, Costa S et\u00a0al (2012) Association between EGF +61 genetic \u00adpolymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-\u00adcontrol study. Tumour Biol 33:1341\u20131348","journal-title":"Tumour Biol"},{"key":"20_CR002075","first-page":"1589","volume":"63","author":"WA Weiss","year":"2003","unstructured":"Weiss WA, Burns MJ, Hackett C et\u00a0al (2003) Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63:1589\u20131595","journal-title":"Cancer Res"},{"key":"20_CR002076","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/sj.onc.1203520","volume":"19","author":"R Brandt","year":"2000","unstructured":"Brandt R, Eisenbrandt R, Leenders F et\u00a0al (2000) Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 19:2129\u20132137","journal-title":"Oncogene"},{"key":"20_CR002077","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.rppneu.2012.04.011","volume":"18","author":"A Ara\u00fajo","year":"2012","unstructured":"Ara\u00fajo A, Coelho A, de Mello RA et\u00a0al (2012) Personalizing medicine\u2014strategies for implementing the evaluation of ALK rearrangement in non-small-cell lung cancer in Portugal. Rev Port Pneumol 18:244\u2013246. doi:\n                    10.1016\/j.rppneu.2012.04.011","journal-title":"Rev Port Pneumol"},{"key":"20_CR002078","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/carcin\/bgq079","volume":"31","author":"J Dong","year":"2010","unstructured":"Dong J, Dai J, Shu Y et\u00a0al (2010) Polymorphisms in EGFR and VEGF contribute to non-\u00adsmall cell lung cancer survival in a Chinese Population. Carcinogenesis 31:1080\u20131086","journal-title":"Carcinogenesis"},{"key":"20_CR002079","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajhg.2009.09.012","volume":"85","author":"MT Landi","year":"2009","unstructured":"Landi MT, Chatterjee N, Yu K et\u00a0al (2009) A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 85:679\u2013691","journal-title":"Am J Hum Genet"},{"key":"20_CR002080","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/JTO.0b013e3182475028","volume":"7","author":"H Ito","year":"2012","unstructured":"Ito H, MacKay JD, Hosono S et\u00a0al (2012) Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population. J Thorac Oncol 7:790\u2013798","journal-title":"J Thorac Oncol"},{"key":"20_CR002081","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2012.02165.x","volume":"17","author":"EY Bae","year":"2012","unstructured":"Bae EY, Lee SY, Kang BK et\u00a0al (2012) Replication of results of genome\u2010wide association studies on lung cancer susceptibility loci in a Korean population. Respirology 17:699\u2013706","journal-title":"Respirology"},{"key":"20_CR002082","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(10)70042-5","volume":"11","author":"Y Li","year":"2010","unstructured":"Li Y, Sheu C, Ye Y et\u00a0al (2010) Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 11:321\u2013330","journal-title":"Lancet Oncol"},{"key":"20_CR002083","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1101\/gr.4537706","volume":"16","author":"J Taylor","year":"2006","unstructured":"Taylor J, Tyekucheva S, King DC et\u00a0al (2006) ESPERR: learning strong and weak signals in genomic sequence alignments to identify functional elements. Genome Res 16:1596\u20131604","journal-title":"Genome Res"},{"key":"20_CR002084","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrc1142","volume":"3","author":"DM Feldser","year":"2003","unstructured":"Feldser DM, Hackett JA, Greider CW (2003) Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 3:623\u2013627","journal-title":"Nat Rev Cancer"},{"key":"20_CR002085","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/JTO.0b013e3181886713","volume":"3","author":"I Fernandez-Garcia","year":"2008","unstructured":"Fernandez-Garcia I, Ortiz-de-Solorzano C, Montuenga LM (2008) Telomeres and telomerase in lung cancer. J Thorac Oncol 3:1085\u20131088","journal-title":"J Thorac Oncol"},{"key":"20_CR002086","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/sj.bjc.6601643","volume":"90","author":"S Lantuejoul","year":"2004","unstructured":"Lantuejoul S, Soria J, Moro-Sibilot D et\u00a0al (2004) Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 90:1222\u20131229","journal-title":"Br J Cancer"},{"key":"20_CR002087","doi-asserted-by":"crossref","first-page":"10155","DOI":"10.1073\/pnas.0709618105","volume":"105","author":"S Aviel-Ronen","year":"2008","unstructured":"Aviel-Ronen S, Coe BP, Lau SK et\u00a0al (2008) Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci USA 105:10155\u201310160","journal-title":"Proc Natl Acad Sci U S A"},{"key":"20_CR002088","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/ng.273","volume":"40","author":"Y Wang","year":"2008","unstructured":"Wang Y, Broderick P, Webb E et\u00a0al (2008) Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 40:1407\u20131409","journal-title":"Nat Genet"},{"key":"20_CR002089","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/01.CIR.93.8.1493","volume":"93","author":"V Vincenti","year":"1996","unstructured":"Vincenti V, Cassano C, Rocchi M, Persico MG (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93:1493\u20131495","journal-title":"Circulation"},{"key":"20_CR002090","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s13277-011-0306-y","volume":"33","author":"NA Naik","year":"2012","unstructured":"Naik NA, Bhat IA, Afroze D et\u00a0al (2012) Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India). Tumour Biol 33:833\u2013839","journal-title":"Tumour Biol"},{"key":"20_CR002091","first-page":"812","volume":"63","author":"A Stevens","year":"2003","unstructured":"Stevens A, Soden J, Brenchley P et\u00a0al (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812\u2013816","journal-title":"Cancer Res"},{"key":"20_CR002092","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11912-010-0085-4","volume":"12","author":"S Vaziri","year":"2010","unstructured":"Vaziri S, Kim J, Ganapathi M, Ganapathi R (2010) Vascular endothelial growth factor polymorphisms: Role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 12:102\u2013108","journal-title":"Curr Oncol Rep"},{"key":"20_CR002093","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1158\/1078-0432.CCR-07-1655","volume":"14","author":"R Zhai","year":"2008","unstructured":"Zhai R, Liu G, Zhou W et\u00a0al (2008) Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 14:612\u2013617","journal-title":"Clin Cancer Res"},{"key":"20_CR002094","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1634\/theoncologist.12-2-211","volume":"12","author":"L Toschi","year":"2007","unstructured":"Toschi L, Cappuzzo F (2007) Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 12:211\u2013220","journal-title":"Oncologist"},{"key":"20_CR002095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0014-4827(02)00105-2","volume":"284","author":"R Harris","year":"2003","unstructured":"Harris R, Chung E, Coffey R (2003) EGF receptor ligands. Exp Cell Res 284:2\u201313","journal-title":"Exp Cell Res"},{"key":"20_CR002096","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1097\/01.JTO.0000269737.05962.a0","volume":"2","author":"FA Shepherd","year":"2007","unstructured":"Shepherd FA, Rosell R (2007) Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2:S68\u2013S76","journal-title":"J Thorac Oncol"},{"key":"20_CR002097","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/JTO.0b013e31816de2b8","volume":"3","author":"J Sculier","year":"2008","unstructured":"Sculier J, Chansky K, Crowley J et\u00a0al (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM classification of malignant tumors and the proposals for the 7th Edition. J Thorac Oncol 3:457\u2013466","journal-title":"J Thorac Oncol"},{"key":"20_CR002098","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-04-2661","volume":"11","author":"S Singhal","year":"2005","unstructured":"Singhal S, Vachani A, Antin-Ozerkis D et\u00a0al (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11:3974\u20133986","journal-title":"Clin Cancer Res"},{"key":"20_CR002099","first-page":"777","volume":"364","author":"L Shen","year":"2011","unstructured":"Shen L, Ji H (2011) More on crizotinib. N Engl J Med 364:777","journal-title":"N Engl J Med"},{"key":"20_CR0020100","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M et\u00a0al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247\u20134253","journal-title":"J Clin Oncol"},{"key":"20_CR0020101","first-page":"896","volume-title":"DeVita, Hellman, and Rosenberg\u2019s cancer: principles & practice of oncology","author":"D Schrump","year":"2008","unstructured":"Schrump D, Giaccone G, Kelsey K, Marks L (2008) Non small cell lung cancer. In: DeVita V, Lawrence T, Rosenberg S et\u00a0al (eds) DeVita, Hellman, and Rosenberg\u2019s cancer: principles & practice of oncology, 8th edn. Lippincott Williams & Wilkins, Philadelphia, pp 896\u2013939","edition":"8"},{"key":"20_CR0020102","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1371\/journal.pmed.0020225","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao W, Miller V, Politi K et\u00a0al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:225\u2013235","journal-title":"PLoS Med"},{"key":"20_CR0020103","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","volume":"355","author":"KA Olaussen","year":"2006","unstructured":"Olaussen KA, Dunant A, Fouret P et\u00a0al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983\u2013991","journal-title":"N Engl J Med"},{"key":"20_CR0020104","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1111\/j.1349-7006.2009.01253.x","volume":"100","author":"K Masago","year":"2009","unstructured":"Masago K, Fujita S, Kim Y et\u00a0al (2009) Effect of vascular endothelial growth factor polymorphisms on survival in advanced stage non small cell lung cancer. Cancer Sci 100:1917\u20131922","journal-title":"Cancer Sci"},{"key":"20_CR0020105","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/JTO.0b013e318186a272","volume":"3","author":"E Dajczman","year":"2008","unstructured":"Dajczman E, Kasymjanova G, Kreisman H et\u00a0al (2008) Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 3:1133\u20131136","journal-title":"J Thorac Oncol"},{"key":"20_CR0020106","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","volume":"22","author":"R P\u00e9rez-Soler","year":"2004","unstructured":"P\u00e9rez-Soler R, Chachoua A, Hammond L et\u00a0al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238\u20133247","journal-title":"J Clin Oncol"},{"key":"20_CR0020107","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2007.13.0062","volume":"26","author":"V Miller","year":"2008","unstructured":"Miller V, Riely G, Zakowski M et\u00a0al (2008) Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26:1472\u20131478","journal-title":"J Clin Oncol"},{"key":"20_CR0020108","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1200\/JCO.2010.31.8162","volume":"29","author":"W Brugger","year":"2011","unstructured":"Brugger W, Triller N, Blasinska-Morawiec M et\u00a0al (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113\u20134120","journal-title":"J Clin Oncol"},{"key":"20_CR0020109","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1535-7163.MCT-09-0302","volume":"8","author":"L Jain","year":"2009","unstructured":"Jain L, Vargo CA, Danesi R et\u00a0al (2009) The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8:2496\u20132508","journal-title":"Mol Cancer Ther"},{"key":"20_CR0020110","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/BF03401865","volume":"7","author":"P Zacharatos","year":"2001","unstructured":"Zacharatos P, Kotsinas A, Tsantoulis P et\u00a0al (2001) Relationship of the K-ras\/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas. Mol Med 7:590\u2013597","journal-title":"Mol Med"},{"key":"20_CR0020111","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1200\/JCO.2007.13.5947","volume":"26","author":"RS Heist","year":"2008","unstructured":"Heist RS, Zhai R, Liu G et\u00a0al (2008) VEGF polymorphisms and survival in early-stage non-\u00adsmall-cell lung cancer. J Clin Oncol 26:856\u2013862","journal-title":"J Clin Oncol"},{"key":"20_CR0020112","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lungcan.2009.02.020","volume":"66","author":"M Bieniasz","year":"2009","unstructured":"Bieniasz M, Oszajca K, Eusebio M et\u00a0al (2009) The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer 66:319\u2013326","journal-title":"Lung Cancer"},{"key":"20_CR0020113","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/1055-9965.EPI-04-0472","volume":"14","author":"SJ Lee","year":"2005","unstructured":"Lee SJ, Lee SY, Jeon HS et\u00a0al (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 14:571\u2013575","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"20_CR0020114","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-012-1980-1","volume":"133","author":"P Rodrigues","year":"2012","unstructured":"Rodrigues P, Furriol J, Tormo E et\u00a0al (2012) The single-nucleotide polymorphisms +936 C\/T VEGF and -710 C\/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat 2012 Jun;133(2):769\u2013778","journal-title":"Breast Cancer Res Treat 2012 Jun"},{"key":"20_CR0020115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.lungcan.2004.04.037","volume":"46","author":"M Koukourakis","year":"2004","unstructured":"Koukourakis M, Papazoglou D, Giatromanolaki A et\u00a0al (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293\u2013298","journal-title":"Lung Cancer"},{"key":"20_CR0020116","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1158\/0008-5472.CAN-10-2614","volume":"71","author":"F Yang","year":"2011","unstructured":"Yang F, Tang X, Riquelme E et\u00a0al (2011) Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 71:5512\u20135521","journal-title":"Cancer Res"},{"key":"20_CR0020117","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P et\u00a0al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227\u20131234","journal-title":"J Clin Oncol"},{"key":"20_CR0020118","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ejca.2012.03.007","volume":"48","author":"S Couraud","year":"2012","unstructured":"Couraud S, Zalcman G, Milleron B et\u00a0al (2012) Lung cancer in never smokers\u2014a review. Eur J Cancer 48:1299\u20131311","journal-title":"Eur J Cancer"},{"key":"20_CR0020119","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1158\/1078-0432.CCR-10-2877","volume":"17","author":"Y Li","year":"2011","unstructured":"Li Y, Sun Z, Cunningham JM et\u00a0al (2011) Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res 17:3830\u20133840","journal-title":"Clin Cancer Res"},{"key":"20_CR0020120","first-page":"642","volume":"14","author":"F Ma","year":"2011","unstructured":"Ma F, Xu B, Lin D et\u00a0al (2011) [Effect of rs2293347 polymorphism in EGFR on the clinical efficacy of gefitinib in patients with non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 14:642\u2013645","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"20_CR0020121","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.ejca.2011.04.018","volume":"47","author":"Q Nie","year":"2011","unstructured":"Nie Q, Yang X, An S et\u00a0al (2011) CYP1A1* 2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) n polymorphism. Eur J Cancer 47:1962\u20131970","journal-title":"Eur J Cancer"},{"key":"20_CR0020122","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1513\/pats.200808-099LC","volume":"6","author":"G Dy","year":"2009","unstructured":"Dy G, Adjei A (2009) Emerging therapeutic targets in non-small cell lung cancer. Proc Am Thorac Soc 6:218\u2013223","journal-title":"Proc Am Thorac Soc"}],"container-title":["Biochemical Basis and Therapeutic Implications of Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-5857-9_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T01:30:47Z","timestamp":1557624647000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4614-5857-9_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9781461458562","9781461458579"],"references-count":122,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-5857-9_20","relation":{},"subject":[],"published":{"date-parts":[[2013]]}}}